Underground MDMA-, LSD-and 2-CB-assisted individual and group psychotherapy in Zurich: Outcomes, implications and commentary

Psychedelic substances have long been used in non-Western and archaic cultures for psycho-spiritual purposes and were the focus of substantial psychiatric research after LSD's discovery in 1943. That clinical research largely ceased by the 1970s amid widespread recreational use, and only in recent decades has interest resumed in using such compounds as adjuncts to psychotherapy. Despite the hiatus in formal research, the authors note continuing pockets of underground psychedelic-assisted psychotherapy worldwide. This paper presents a descriptive account of one such underground project in Zurich, reconstructed from several interviews between UK psychiatrist Ben Sessa and German psychiatrist Friederike Fischer. The account aims to describe the therapist's training and practice, the structure and content of individual and group psycholytic sessions, client characteristics and reported outcomes, and the legal, ethical and clinical implications of the project in the context of a resurging formal research field in psychedelics.

The paper is a qualitative, descriptive case account based on interviews between Sessa and Friederike Fischer and on material from the therapist's records and testimony. It reports on a single psychotherapist's private practice in Zurich that delivered psycholytic psychotherapy using MDMA, LSD and 2-CB in individual and monthly weekend group formats over several years until 2009. The extracted text does not present a formal methods section, randomisation, control groups or standardised outcome measurement; rather it describes procedures, client selection and the therapeutic milieu. Friederike's professional background is detailed: medical training in Germany with specialisation in psychotherapy, additional training in Holotropic Breathwork with Stanislav Grof, and participation in a late-1980s/early-1990s Swiss psycholytic therapy training group. The authors define psycholytic therapy as repeated low-to-moderate dosing in the context of psychotherapy, contrasting it with single high-dose 'psychedelic' sessions. Client selection and sample descriptors are reported: 97 clients underwent psycholytic therapy, 60 of whom participated in the psycholytic groups; gender was approximately equal and ages ranged from 18 to 70. Only about 4% of her broader non-drug therapy caseload proceeded to drug-assisted work. Sessions were delivered in a private-home setting once monthly over a weekend, with a structured sequence of rituals, silence, music and phased dosing (typically beginning with MDMA and adding LSD or 2-CB mid-session). Dosage decisions were set by the therapist for beginners and negotiated with experienced participants. Safety and follow-up practices included pre-session psychoeducation, a written protocol required for entry to each session, a written integration report submitted within two weeks, optional ad hoc non-drug individual sessions and continuous availability of the therapist. No routine quantitative psychological outcome measures were collected, and the extracted text indicates the analysis is narrative and qualitative rather than statistical.

Reported participant numbers and engagement: 97 clients received psycholytic therapy; 60 participated in the organised psycholytic groups. The typical participant stayed for an average of 25 sessions over several years. Most participants were described as well educated and intellectually engaged; selection to drug-assisted work was conservative, comprising approximately 4% of the non-drug therapy pool. Therapeutic procedures and substances: sessions usually began with MDMA, with LSD or 2-CB added later so that the peaks overlapped; occasionally sessions started with LSD or 2-CB and other agents such as ayahuasca or psilocybin were used rarely. All participants at a given session took the same substance at the same time, with dose variation between individuals. Sessions followed a weekend structure of preparatory non-drug meetings, an all-day Saturday of drug-assisted work with music, silence and therapist-led individual and group interventions, followed by an integration meeting on Sunday. Cost to guests was reported as 300–400 Swiss Francs per weekend. Clinical outcomes as reported by the therapist and participants were predominantly positive on qualitative grounds: almost all clients described improved relationships and well-being at home and at work; examples include career changes and altered relationship decisions. The text reports no serious adverse reactions among clients while undergoing psycholytic therapy: specifically, no cases of psychosis, no hospitalisations and no suicides are reported within the treated cohort. The extracted material, however, emphasises that standardised quantitative outcome measures were not routinely collected, so these observations are narrative rather than measured. Legal outcomes and aftermath: in 2009 an ex-client notified police, leading to surveillance and a raid that recovered a small number of MDMA tablets/capsules and LSD blotters plus documentation. Arrests and detention followed but investigators found no evidence of drug dealing. At trial in 2010 the prosecution alleged drug dealing and societal endangerment; expert witnesses for the defence contested LSD's dangerousness in controlled settings and argued the practice had employed careful attention to set and setting. The court rejected the endangering-society charge; sentencing was relatively lenient. Konrad (the therapist's husband) was fined 10,000 Swiss Francs and given a two-year probation; Friederike was fined 2,000 Swiss Francs and received a 16-month suspended sentence with two years probation. Media vilification followed, professional disciplinary threats occurred and Friederike relinquished her psychotherapist qualification. Risks noted beyond this practice: the paper cites two deaths in 2009 in Berlin associated with an underground group where patients were mistakenly given lethal doses of methylone, underscoring risks when quality control and clinical governance are absent.

The authors use this case to raise multiple clinical, legal and ethical questions about underground psycholytic practice. They emphasise that, in this instance, the therapist reported careful attention to set and setting, conservative client selection and extensive follow-up, which the authors argue contributed to the absence of reported serious adverse events in this cohort. At the same time, the therapists' isolation and inability to seek supervision or institutional support are identified as important vulnerabilities; the paper notes a boundary breach when an ex-client's ex-husband lodged briefly with the couple, and the authors reflect that such proximity may have contributed to the breakdown that precipitated the complaint. The lack of external oversight meant no ready avenues for legal, clinical or insurance support if problems arose. Ethically, the narrative confronts the tension between legal prohibition and perceived clinical need: some drugs with greater population harms remain legal and socially sanctioned, while substances with potential therapeutic value remain criminalised. The authors frame Friederike's decision to provide illicit therapy as ethically ambiguous—questioning whether she was an unethical law‑breaker or a clinician taking personal risk to offer a treatment option otherwise unavailable. They also highlight that public misconceptions (including accusations of profiteering and cult-like behaviour) exacerbated the personal and professional fallout despite evidence presented at trial that the project was not commercially exploitative. In terms of broader implications, the paper situates the case within a resurgent formal research agenda for psychedelics, noting contemporary clinical studies on DMT, ketamine-assisted approaches for dependence, psilocybin for obsessive–compulsive disorder and MDMA for PTSD. The authors suggest that if current research continues, regulated, legal and monitored psychedelic-assisted therapies could become available within 10–15 years. They argue for adopting an evidence-based medical language to communicate findings to the mainstream profession while also recognising that transpersonal phenomena (bliss, self-realisation) that commonly arise in psychedelic sessions pose a challenge for bio-medical description. Finally, the authors call for revision of outdated drug classifications and scheduling that impede research and clinical implementation. Limitations acknowledged in the text include the absence of routine quantitative outcome measures, the descriptive and non-systematic nature of the account, and the fact this is an isolated case report that cannot establish safety or efficacy more generally. The authors therefore present the narrative as illustrative and caution against generalising from it without further controlled study.